Tasimelteon

David N. Neubauer, Ahmed S. BaHammam, Seithikurppu R. Pandi-Perumal

Research output: Contribution to journalArticle

Abstract

The role of the melatonin in relation with circadian rhythms and the sleep/wake cycle is well established. It is thought to play a role in controlling the sleep–wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus. In normal subjects, the endogenous circadian period is a little over 24 h, but is entrained to the 24-h day through exposure to light. In the absence of light or light perception (totally blind), the synchronization is lost and the circadian rhythm follows the intrinsic non-24 h clock, resulting in a non-24 h sleep–wake disorder. Non-24 h sleep–wake disorder is characterized by a misalignment of the 24-h light/dark (LD) cycle and a non-entrained sleep/wake cycle propensity resulting in asymptomatic periods alternating with episodes of insomnia, excessive daytime sleepiness (EDS), or a combination of both. Tasimelteon (VEC-162) is an orally bioavailable melatonin receptor agonist of the melatonin MT1 and MT2 receptors recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24 h sleep–wake rhythm disorder.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalMilestones in Drug Therapy
Volume49
DOIs
StatePublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Neubauer, D. N., BaHammam, A. S., & Pandi-Perumal, S. R. (2015). Tasimelteon. Milestones in Drug Therapy, 49, 261-269. https://doi.org/10.1007/978-3-319-11514-6_13